Physician profile
Stephanie Langsam
NPI 1801235056
$3,539.39
in general payments reported to CMS, 2019-2025
36 companies · $977 in 2025
The $977 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $689 · 2020: $391 · 2021: $255 · 2022: $248 · 2023: $293 · 2024: $685 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.59 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $635.03 | 2019-2025 | Veozah |
| Abbvie INC. | $482.02 | 2019-2023 | |
| Exeltis, USA INC. | $287.44 | 2019-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $239.99 | 2019-2024 | |
| Evofem Biosciences, INC. | $215.93 | 2021-2025 | Phexxi, Solosec, Phexx |
| Davol INC. | $193.10 | 2025 | Arista |
| Sage Therapeutics, LLC | $154.79 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $146.08 | 2019-2021 | |
| Lupin INC. | $144.00 | 2019-2020 | |
| Coopersurgical, INC. | $127.42 | 2023-2025 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $103.36 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $81.82 | 2024-2025 | Myfembree |
| Hologic Sales and Service, LLC | $62.07 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Mayne Pharma Commercial LLC | $61.12 | 2023-2025 | |
| Millicent US INC | $53.17 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $50.38 | 2019 | |
| Shield Therapeutics INC | $39.92 | 2024 | |
| Supernus Pharmaceuticals, INC. | $39.83 | 2025 | Qelbree |
| Baxter Healthcare | $36.09 | 2019 | |
| Organon LLC | $31.77 | 2024 | |
| Amag Pharmaceuticals, INC. | $31.18 | 2019-2020 | |
| Smith+Nephew, INC. | $29.54 | 2020 | |
| Merck Sharp & Dohme LLC | $27.56 | 2019 | |
| Ascend Therapeutics US, LLC | $27.34 | 2020 | |
| Avion Pharmaceuticals | $26.84 | 2020-2021 | |
| Daiichi Sankyo INC. | $24.60 | 2019 | |
| Amgen INC. | $24.15 | 2020 | |
| Radius Health, INC. | $23.12 | 2019 | |
| Myovant Sciences INC. | $23.06 | 2021 | |
| Ibsa Pharma INC. | $21.10 | 2023 | Tirosint, Licart |
| Agile Therapeutics, INC. | $18.71 | 2021 | |
| Convatec INC. | $17.48 | 2025 | |
| Roche Diagnostics Corporation | $16.38 | 2019 | |
| Medicem INC. | $16.34 | 2020 | |
| Duchesnay USA Incorporated | $14.69 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Langsam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.